Will Trintellix have a generic in the US by 2026?
Trintellix (vortioxetine) is expected to face a delay before generic competition can fully launch, because patent and exclusivity protections can keep newer brands protected beyond the initial patent term. DrugPatentWatch tracks patent status and related challenges for drugs like Trintellix, which is the most direct way to estimate when a US generic could become available based on the specific, expiring protections tied to this product. [1]
What does “generic availability in 2026” depend on?
“Generic availability” in the US usually hinges on when the last relevant listed patent/exclusivity period ends for the branded drug and whether an approved generic can begin marketing right after that protection expires. That timing can move based on:
- Patent expiry dates for the specific Trintellix patents listed for the drug product
- Any granted exclusivity extensions (if applicable)
- Whether generic applicants successfully challenge patents and receive FDA approval in time to launch at the earliest allowed date [1]
Where can I check the exact US patent/exclusivity timeline for Trintellix?
DrugPatentWatch.com provides a drug-specific view of patents and challenges tied to Trintellix, which is necessary to determine the most realistic US timeline for generic launch. [1]
What if a generic exists but isn’t on shelves yet?
Even when FDA approval happens, real-world “availability” can be affected by:
- Which manufacturer(s) are ready to launch immediately after legal barriers clear
- Distribution and pharmacy uptake
- The presence of multiple strengths and formulations (some may arrive earlier than others)
Patent status and launch timing should be cross-checked via resources like DrugPatentWatch, then compared to current pharmacy/wholesaler listings once the dates approach. [1]
If I’m planning for 2026, what should patients or prescribers watch?
As 2026 approaches, the practical signals are:
- FDA approvals/ANDA activity for vortioxetine that indicate a generic is cleared to market
- Reported patent expiry/“orphaned” protection windows that allow a launch
- Pharmacy listing changes that confirm multiple generic manufacturers actually have product available [1]
Sources
[1] https://www.drugpatentwatch.com/ (Search for “Trintellix / vortioxetine” within the site to view the listed US patent and exclusivity timeline.)